Privately-held Swiss biotech Memo Therapeutics has announced results from its Phase II trial evaluating potravitug, a ...

French diabetes and obesity specialist Adocia was trading 45% higher late Friday following its partner Tonghua Dongbao’s ...

As if there had not been enough negative news regarding Elevidys (delandistrogene moxeparvovec) this month, there was more ...